We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Detects 12 Common Cancers Before Symptoms Appear

By LabMedica International staff writers
Posted on 28 Apr 2025
Print article
Image: The technology measures microRNA expression in a small amount of blood to identify the presence of cancer (Photo courtesy of Shutterstock)
Image: The technology measures microRNA expression in a small amount of blood to identify the presence of cancer (Photo courtesy of Shutterstock)

Bowel cancer is the fourth most common cancer in the UK, with over 42,000 new diagnoses each year. Detecting bowel cancer in its early stages can be challenging, and as the disease progresses, survival rates significantly decrease due to fewer available treatment options. Early detection is essential, as 9 in 10 people survive bowel cancer when it is identified at stage 1, compared to only 1 in 10 when diagnosed at stage 4. Now, patients may soon benefit from cutting-edge technology that could enable earlier, faster, and more cost-effective diagnoses, reducing the need for invasive procedures like colonoscopies and biopsies, and saving critical time.

Xgenera (Hampshire, UK), in collaboration with the University of Southampton (Southampton, UK), has developed an AI-powered blood test that holds promise for earlier detection of bowel cancer, improving diagnosis rates, and giving patients valuable time to receive more timely and effective treatment. The AI-driven test, named miONCO-Dx, was developed using data from over 20,000 patients and has been optimized into a faster, cheaper, and more scalable solution, representing a major breakthrough. The test works by measuring microRNA in a blood sample and using AI to determine the presence of cancer and its location in the body.

This simple blood test could detect cancer earlier, when treatment is not only more effective but also less costly and easier, potentially helping to conserve valuable healthcare resources in the long term. Early trials have shown promising results, with the test demonstrating over 99% accuracy in identifying 12 of the most common and deadly cancers, including bowel cancer. The UK government, in partnership with the National Institute for Health and Care Research (NIHR), has granted GBP 2.4 million to further the development of miONCO-Dx. The test will soon be evaluated in a clinical trial involving 8,000 patients, marking a significant milestone towards making this technology accessible to patients.

“This blood test has the potential to help us detect bowel cancer earlier and reduce the need for invasive tests, and the next step in this trial will now be vital in gathering further evidence on its effectiveness and how it could work in practice,” said Professor Sir Stephen Powis, NHS National Medical Director.

Related Links:
Xgenera
University of Southampton

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The researchers detected genomic alterations from plasma cfDNA (Photo courtesy of 123RF)

Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors

Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.